NCT07431840 · Quantec Ltd
Immune Defense Protein Impact On Respiratory Immune Outcomes
What this study is about
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability.
View original scientific description
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Interventions
DIETARY_SUPPLEMENT
Immune Defense Protein 50mg Dose
IDP dose of 50mg
DIETARY_SUPPLEMENT
IDP 200mg Dose
IDP dose of 200mg
DIETARY_SUPPLEMENT
Matching Placebo
Matching Placebo
Primary outcome measures
Impact on Upper Respiratory Symptom Incidence, Duration and Severity
Time frame: 17 weeks
To evaluate the impact of IDP® Preventative Supplementation on incidence of upper respiratory symptoms, and the duration and severity of any symptoms that occur by measuring the change in incidence of upper respiratory symptoms (frequency, type, duration and severity) between study product and placebo groups. Baseline will be compared as well.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age 60 years and older
- Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
- Able to read and understand English.
- Able to read, understand, and provide informed consent.
- Able to use a personal smartphone device and download Chloe by People Science.
- Able to receive shipment of the product at an address within the United States.
Exclusion criteria
- Any potential participants who:
- Do not have a personal smartphone, internet access, or unwilling to download Chloe.
- Already in an immunocompromised state, including: A. Infectious Causes
- Chronic hepatitis B or C (advanced stages)
- Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
- Leukemia (e.g., AML, ALL, CLL)
- Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
- Multiple Myeloma
- Any metastatic cancer receiving chemotherapy C. Immunosuppressive Therapy: Participants on:
- Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
- Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
- Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)
- mTOR inhibitors (e.g., sirolimus)
- JAK inhibitors (e.g., tofacitinib)
- Chemotherapy or radiation therapy
- Anti-rejection meds post-organ transplant D. Transplant Patients
- Solid organ transplant (kidney, liver, heart, lung)
- Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus (SLE)
- Psoriasis or Psoriatic Arthritis
- Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis)
- Multiple Sclerosis (especially on disease-modifying therapies)
- Other Concomitant Conditions and Therapies:
- Any investigational therapies or treatments within 30 days prior to enrollment.
- Known diagnosis of Asthma and/or COPD
- Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
- Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes
- Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes
- Use of cannabis-containing products daily
- Use of nicotine-containing products daily
- Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids.
- Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.
Where
- Los Angeles, California
Collaborators
People Science, Inc.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 12, 2026 · Source of record for eligibility and locations